Masatoshi Kudo1, Riccardo Lencioni2, Jorge A Marrero3, Alan P Venook4, Jean-Pierre Bronowicki5, Xiao-Ping Chen6, Lucy Dagher7, Junji Furuse8, Jean-Francois H Geschwind9, Laura Ladrón de Guevara10, Christos Papandreou11, Arun J Sanyal12, Tadatoshi Takayama13, Seung Kew Yoon14, Keiko Nakajima15, Robert Lehr16, Stephanie Heldner17, Sheng-Long Ye18. 1. Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka, Japan. 2. Division of Diagnostic Imaging and Intervention, Pisa University Hospital and School of Medicine, Pisa, Italy. 3. Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA. 4. University of California, San Francisco, CA, USA. 5. Department of Gastroenterology and Hepatology, INSERM U954, University Hospital, University of Lorraine, Nancy, France. 6. Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. 7. Policlínica Metropolitana, Caracas, Venezuela. 8. Kyorin University School of Medicine, Tokyo, Japan. 9. Vascular and Interventional Radiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 10. Hospital Angeles Clínica Londres, Mexico City, Mexico. 11. University Hospital of Larissa, Larissa, Greece. 12. Virginia Commonwealth University Medical Center, Richmond, VA, USA. 13. Department of Digestive Surgery, Nihon University School of Medicine, Tokyo, Japan. 14. The Catholic University of Korea, Seoul, Korea. 15. Global Medical Affairs, Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA. 16. Clinical Statistics, Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA. 17. Global Medical Affairs and Pharmacovigilance, Bayer Pharma AG, Berlin, Germany. 18. Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China.
Abstract
BACKGROUND & AIMS: Treatment approaches for hepatocellular carcinoma (HCC) vary across countries, but these differences and their potential impact on outcomes have not been comprehensively assessed. Data from the multinational GIDEON (Global Investigation of therapeutic DEcisions in HCC and Of its treatment with sorafeNib) registry evaluated differences in patient characteristics, practice patterns and outcomes in HCC across geographical regions in patients who received sorafenib. METHODS: GIDEON is a non-randomised, observational registry study conducted in 39 countries across five global regions. HCC patients in whom a decision to treat with sorafenib was made in clinical practice and according to local practices were included. RESULTS: 3202 patients were evaluable for safety analysis: Asia-Pacific (n = 928), Japan (n = 508), Europe (n = 1113), USA (n = 563) and Latin America (n = 90). Patients in Japan had earlier-stage disease at initial diagnosis compared with patients in other regions (Barcelona Clinic Liver Cancer stage A; 43.7% vs 9.1-24.3%). Use of locoregional therapies before sorafenib, including transarterial chemoembolisation, was more common in Japan (84.4%) and Asia-Pacific (67.2%) compared with the USA (49.4%) and Europe (43.5%). Treatment patterns with respect to sorafenib also differed, with a shorter duration of treatment reported in the USA and Asia-Pacific. Time from initial diagnosis to death was longer in Japan compared with other regions (median, 79.6 months vs 14.8-25.0 months). CONCLUSIONS: Data from GIDEON highlight regional variations in the management of HCC and patient outcomes. Greater standardisation of management may help optimise outcomes for HCC patients.
BACKGROUND & AIMS: Treatment approaches for hepatocellular carcinoma (HCC) vary across countries, but these differences and their potential impact on outcomes have not been comprehensively assessed. Data from the multinational GIDEON (Global Investigation of therapeutic DEcisions in HCC and Of its treatment with sorafeNib) registry evaluated differences in patient characteristics, practice patterns and outcomes in HCC across geographical regions in patients who received sorafenib. METHODS: GIDEON is a non-randomised, observational registry study conducted in 39 countries across five global regions. HCC patients in whom a decision to treat with sorafenib was made in clinical practice and according to local practices were included. RESULTS: 3202 patients were evaluable for safety analysis: Asia-Pacific (n = 928), Japan (n = 508), Europe (n = 1113), USA (n = 563) and Latin America (n = 90). Patients in Japan had earlier-stage disease at initial diagnosis compared with patients in other regions (Barcelona Clinic Liver Cancer stage A; 43.7% vs 9.1-24.3%). Use of locoregional therapies before sorafenib, including transarterial chemoembolisation, was more common in Japan (84.4%) and Asia-Pacific (67.2%) compared with the USA (49.4%) and Europe (43.5%). Treatment patterns with respect to sorafenib also differed, with a shorter duration of treatment reported in the USA and Asia-Pacific. Time from initial diagnosis to death was longer in Japan compared with other regions (median, 79.6 months vs 14.8-25.0 months). CONCLUSIONS: Data from GIDEON highlight regional variations in the management of HCC and patient outcomes. Greater standardisation of management may help optimise outcomes for HCC patients.
Authors: Mozhdeh Sojoodi; Lan Wei; Derek J Erstad; Suguru Yamada; Tsutomu Fujii; Hadassa Hirschfield; Rosa S Kim; Gregory Y Lauwers; Michael Lanuti; Yujin Hoshida; Kenneth K Tanabe; Bryan C Fuchs Journal: Cancer Prev Res (Phila) Date: 2020-04-06
Authors: Changhoon Yoo; Joong-Won Park; Yoon Jun Kim; Do Young Kim; Su Jong Yu; Tae Seop Lim; Su Jin Lee; Baek-Yeol Ryoo; Ho Yeong Lim Journal: Invest New Drugs Date: 2018-12-07 Impact factor: 3.850
Authors: Dominik Bettinger; David J Pinato; Michael Schultheiss; Rohini Sharma; Lorenza Rimassa; Tiziana Pressiani; Michela E Burlone; Mario Pirisi; Masatoshi Kudo; Joong Won Park; Nico Buettner; Christoph Neumann-Haefelin; Tobias Boettler; Nasrin Abbasi-Senger; Horst Alheit; Wolfgang Baus; Oliver Blanck; Sabine Gerum; Mathias Guckenberger; Daniel Habermehl; Christian Ostheimer; Oliver Riesterer; Jörg Tamihardja; Anca-Ligia Grosu; Robert Thimme; Thomas Baptist Brunner; Eleni Gkika Journal: Liver Cancer Date: 2018-07-12 Impact factor: 11.740